Featured Research

from universities, journals, and other organizations

Thrombosis Patients Face Greater Risks Than Previously Believed

Date:
December 11, 2008
Source:
McGill University
Summary:
Researchers warn that in addition to the well-known risks of pulmonary embolism, deep venous thrombosis patients also face postthrombotic syndrome, a poorly understood, long-term complication not addressed by traditional treatment approaches like blood thinners.

Deep venous thrombosis (DVT), the formation of blood clots in the lower limbs, is the third-most common vascular disease in North America after heart attack and stroke, and is a frequent complication in hospitalized patients.

DVT is a potentially serious condition that can lead to rapid death from pulmonary embolism if untreated, and has become such a serious health concern that the U.S. Surgeon General and the Canadian Safer Healthcare Now! coalition both recently issued highly publicized calls to action to reduce the number of cases of DVT in high risk groups, in part by improving the adoption of preventative measures like the early administration of blood thinners.

However, researchers at McGill University and the affiliated Jewish General Hospital – along with colleagues from Universitι de Montrιal, McMaster University and other institutions – warn that, beyond the well-known risks of pulmonary embolism, DVT patients also face postthrombotic syndrome (PTS), a poorly understood, long-term complication not addressed by traditional treatment approaches like blood thinners. Their conclusions, derived from a large, multicentre Canadian study, were published in the November issue of the Annals of Internal Medicine.

The study followed 387 patients at eight hospital centres in Quebec and Ontario for two years, the researchers said, the first multicentre study of PTS ever undertaken in North America.

"Incredibly, we found as many as 43 per cent of the patients developed postthrombotic syndrome, and one-third of those had moderate to severe cases," said McGill's Dr. Susan R. Kahn, lead author of the study. "The syndrome is characterized by persistent leg pain and swelling, and in severe cases, patients can develop painful leg ulcers which are very difficult to treat.

"Contrary to popular belief, DVT doesn't just affect older people, it can affect adults of all ages," explained Kahn, an associate professor at McGill's Faculty of Medicine and Director of the Thrombosis Program and Associate Director of the Centre for Clinical Epidemiology & Community Studies at the JGH. "Developing postthrombotic syndrome and similar complications have been shown to lead to significant disability, lost workdays and very poor quality of life."

In addition to simply documenting the incidence of PTS, Kahn and her colleagues also attempted to identify risk factors that made certain patients more likely than others to develop it. They discovered that older patients, patients who had suffered a previous bout of DVT and patients with larger blood clots at the time of diagnosis faced a greater risk of developing PTS. Moreover, they also discovered that the risk of developing PTS was far higher in patients still experiencing leg symptoms one month after DVT was first diagnosed and treated.

"This suggests that physicians can predict if a patient is likely to develop chronic PTS as early as one month after DVT diagnosis," Kahn said. "Our results show that current modalities to treat acute DVT are not effective in preventing chronic complications of DVT, and emphasize the need for additional research in the prevention and treatment of PTS."


Story Source:

The above story is based on materials provided by McGill University. Note: Materials may be edited for content and length.


Cite This Page:

McGill University. "Thrombosis Patients Face Greater Risks Than Previously Believed." ScienceDaily. ScienceDaily, 11 December 2008. <www.sciencedaily.com/releases/2008/12/081202153527.htm>.
McGill University. (2008, December 11). Thrombosis Patients Face Greater Risks Than Previously Believed. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/12/081202153527.htm
McGill University. "Thrombosis Patients Face Greater Risks Than Previously Believed." ScienceDaily. www.sciencedaily.com/releases/2008/12/081202153527.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins